Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Balicatib

SKU: orb1225219

Description

Balicatib is an inhibitor of cathepsin K with IC50 value of 1.4nM.Balicatib is highly selective against cathepsin K over cathepsin B, L and S in the in vitro enzyme assay. However, the selectivity is not so high in cell-based enzyme assay. The lysosomotropic character of balicatib results in its accumulation in lysosomes and the subsequent nonselective off-target effects. The off-target effects also cause the skin adverse events of balicatib. As a cathepsin K inhibitor, balicatib is developed for osteoporosis. It has been reported to reduce the biochemical markers of bone resorption and increase bone mineral density in ovariectomized monkeys.(In Vitro):Balicatib (0-10 μM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 μM in human dermal fibroblasts.(In Vivo):Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys.

Images & Validation

Key Properties

CAS Number354813-19-7
MW411.54
Purity>98% (HPLC)
FormulaC23H33N5O2
SMILESO=C(NC1(C(NCC#N)=O)CCCCC1)C2=CC=C(N3CCN(CCC)CC3)C=C2
TargetCysteine Protease
SolubilitySoluble in DMSO

Bioactivity

In Vivo
Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys. Animal model: 11-13 years, female cynomolgus monkeys (Macaca fascicularis). Dosage: 0, 3, 10, 50 mg/kg. Administration: Oral gavage; twice daily for 18 months. Result: Completely prevented ovariectomy-induced increases in BFR/BS in cancellous bone of vertebra and femur and in osteonal and endocortical bone of vertebra, significantly decreased bone formation rates.
In Vitro
Balicatib (0-10 μM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 μM in human dermal fibroblasts.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

AAE581

Similar Products

  • Balicatib [orb1307327]

    98.17% (May vary between batches)

    354813-19-7

    411.54

    C23H33N5O2

    5 mg, 50 mg, 2 mg, 1 ml x 10 mM (in DMSO), 25 mg, 100 mg, 10 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Balicatib (orb1225219)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

2 mg
$ 80.00
5 mg
$ 100.00
10 mg
$ 160.00
25 mg
$ 330.00
50 mg
$ 590.00
100 mg
$ 840.00
500 mg
$ 1,730.00